PT  - JOURNAL ARTICLE
AU  - Araujo, Carlo S R
AU  - Medeiros-Ribeiro, Ana C
AU  - Saad, Carla G S
AU  - Bonfiglioli, Karina R
AU  - Domiciano, Diogo S
AU  - Shimabuco, Andrea Y
AU  - Silva, Matheus R
AU  - Yuki, Emily F N
AU  - Pasoto, Sandra G
AU  - Pedrosa, Tatiana N
AU  - Kupa, Leonard
AU  - Zou, Gioanna
AU  - Pereira, Rosa M R
AU  - Silva, Clovis A
AU  - Aikawa, Nadia E
AU  - Bonfa, Eloisa
TI  - A RANDOMIZED CLINICAL TRIAL OF 2-WEEK METHOTREXATE DISCONTINUATION IN RHEUMATOID ARTHRITIS PATIENTS VACCINATED WITH INACTIVATED SARS-COV-2 VACCINE
AID  - 10.1101/2021.11.23.21266785
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.11.23.21266785
4099  - http://medrxiv.org/content/early/2021/11/24/2021.11.23.21266785.short
4100  - http://medrxiv.org/content/early/2021/11/24/2021.11.23.21266785.full
AB  - Objectives To evaluate the effect on immunogenicity and safety of 2-week methotrexate(MTX) discontinuation after each dose of the Sinovac-CoronaVac vaccine versus MTX maintenance in rheumatoid arthritis(RA) patients.Methods This was a single-center, prospective, randomized, investigator-blinded, intervention study (#NCT04754698, CoronavRheum), including adult RA patients(stable CDAI<10, prednisone<7.5mg/day), randomized(1:1) to withdraw MTX(MTX-hold) for 2 weeks after each vaccine dose or maintain MTX(MTX-maintain), evaluated at D0, D28 and D69. Co-primary outcomes were anti-SARS-CoV-2 S1/S2 IgG seroconversion(SC) and neutralizing antibody(NAb) positivity at D69. Secondary outcomes were GMT and changes in disease activity scores. For immunogenicity analyses, we excluded patients with baseline positive IgG/NAb, and, for safety reasons, those unable to hold MTX twice(CDAI>10 at D28).Results Randomization included 138 patients with 9 exclusions(5 COVID-19, 4 protocol violations). Safety evaluation included 60(MTX-hold) and 69(MTX-maintain) patients. Further exclusions consisted of 27 patients[13(21.7%) vs. 14(20.3%),p=0.848] with positive baseline IgG/NAb and 10 patients(21.3%) in MTX-hold with CDAI>10 at D28. At D69, a higher increase in SC[29(78.4%) vs 30(54.5%),p=0.019] was observed in MTX-hold(n=37) in comparison to MTX-maintain(n=55), with parallel augmentation in GMT[34.2(25.2-46.4) vs 16.8(11.9-23.6),p=0.006]. No differences were observed for NAb positivity[23(62.2%) vs 27(49.1%),p=0.217]. Longitudinal variations in disease activity scores were alike in both groups(CDAI,p=0.144; DAS28-CRP,p=0.718).Conclusion We provided novel data that 2-week MTX withdrawal after each vaccine dose improves anti-SARS-CoV-2 immunogenicity. The comparable longitudinal variations of disease activity in both groups suggest that discontinuation is a feasible and efficient strategy in well-controlled RA patients, and may be even safer for vaccines with longer interval between doses or single dose schedules.Funding FAPESP/CNPq/B3-Bolsa de Valores-Brasil.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04754698Funding StatementThis study was sponsored by grants from Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) (no. 2015/037564 to N.E.A., S.G.P., C.A.S. and E.B.; no. 2017/14352-7 to T.P.; no. 2019/17272-0 to L.K.; no. 2021/066160 to G.Z.); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) (no. 305242/20199 to E.B.; no. 304984/20205 to C.A.S.; no. 305556/20177 to R.M.R.P.) and B3 Bolsa de Valores do Brasil. Instituto Butantan supplied the study product and had no other role in the trial.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of the Hospital das Clinicas da Faculdade de Medicina da USP (CAPPesq) gave ethical approval for this work National Ethics committee/IRB (National Comission for Ethics in Research -CONEP) gave ethical approval for this work CAAE: 42566621.0.0000.0068I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors